Marc Michel

Active 1985–2025

153
Papers
18,559
Citations
80
h-index
141
i10-index

Citations

Citations per year for Marc Michel1986: 2 citations1987: 1 citations1988: 5 citations1989: 1 citations1990: 2 citations1991: 3 citations1992: 6 citations1993: 1 citations1994: 3 citations1995: 8 citations1996: 12 citations1997: 8 citations1998: 18 citations1999: 17 citations2000: 17 citations2001: 11 citations2002: 16 citations2003: 20 citations2004: 23 citations2005: 30 citations2006: 29 citations2007: 36 citations2008: 41 citations2009: 65 citations2010: 62 citations2011: 67 citations2012: 58 citations2013: 57 citations2014: 92 citations2015: 97 citations2016: 83 citations2017: 102 citations2018: 100 citations2019: 387 citations2020: 671 citations2021: 839 citations2022: 627 citations2023: 457 citations2024: 707 citations2025: 308 citations2026: 13 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,272 citing papers, 21.6% of this breakdownChina: 524 citing papers, 8.9% of this breakdownFrance: 460 citing papers, 7.8% of this breakdownUnited Kingdom: 426 citing papers, 7.2% of this breakdownItaly: 398 citing papers, 6.8% of this breakdownGermany: 259 citing papers, 4.4% of this breakdownCanada: 213 citing papers, 3.6% of this breakdownNetherlands: 174 citing papers, 3% of this breakdownSpain: 167 citing papers, 2.8% of this breakdownAustralia: 149 citing papers, 2.5% of this breakdownJapan: 146 citing papers, 2.5% of this breakdownSwitzerland: 142 citing papers, 2.4% of this breakdown
0%21.6%Other 26.5%

Fields

  • Medicine77.5%
  • Immunology and Microbiology9.2%
  • Biochemistry, Genetics and Molecular Biology6.7%
  • Materials Science3%
  • Engineering1.1%
  • Environmental Science0.4%
  • Other2.1%

Topics

  • Platelet Disorders and Treatments8.4%
  • Blood groups and transfusion7.5%
  • SARS-CoV-2 and COVID-19 Research5.2%
  • COVID-19 Clinical Research Studies5.1%
  • Heparin-Induced Thrombocytopenia and Thrombosis2.1%
  • Long-Term Effects of COVID-192%
  • Other69.7%

Coauthors

All papers

Open in search
  1. Updated international consensus report on the investigation and management of primary immune thrombocytopenia

    Authors: , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2019 cited by 1,090

  2. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

    Authors: , , , , , , , , , , , , , , , , , , , - Blood 2008 cited by 2,660

  3. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database

    Authors: , , , , , , , , , , , , , - Scientific Reports 2022 cited by 171

  4. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Aryan Hamed, Árpád Illés, Monica Carpenedo, Andrea Artoni, Monica Bocchia, Barbara Gamberi, Alessandra Borchiellini, Esther Natalie Olíva, Andrea Patriarca, Simona Tomassetti, Yoshitaka Miyakawa, Kiyoshi Ando, Hiroshi Handa, Shinya Katsutani, Kaichi Nishiwaki, Shoko Ito, Tomoki� Ito, Fransien de Boer, A.J. Gerard Jansen, Hanna Ciepłuch, Szymon Fornagiel, Sebastian Grosicki, Maria Soroka‐Wojtaszko, Jacek Treliński, Б. А. Бакиров, Elena Borisenkova, Elena Volodicheva, Yuri Shatokhin, Andrey Proydakov, Maria Aranzazu Alonso, María Eva Mingot‐Castellano, Blanca Sánchez‐González, Blanca Sanchez-Gonzalez, Meltem Aylı, Tuba Hacıbekiroğlu, Ahmet Muzaffer Demir, Meliha Nalçacı, Mehmet Sönmez, Anıl Tombak, Selami Koçak Toprak, Burhan Turgut, Filiz Vural, Münci Yağcı, Fevzi Altuntaş, Mehmet Turgut, Emın Kaya, Nataliya Romanyuk, Vickie McDonald, Syed Rashid Saeed Kazmi, Catherine M. Broome, Spero R. Cataland, Ketan Doshi, Steven R. Lentz, Michael Boxer, Richard Rosenberg, Michael Boxer, Richard Rosenberg - The Lancet 2023 cited by 91

  5. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting

    Authors: , , , , , , , , , , , , - Blood Reviews 2019 cited by 544

  6. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia

    Authors: , , , , , , , , , , , , , , , , - American Journal of Hematology 2019 cited by 181

  7. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Cell 2021 cited by 371

  8. Sutimlimab in Cold Agglutinin Disease

    Authors: , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 210

  9. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?

    Authors: , , , , , , , , , - European Journal of Cancer 2019 cited by 173

  10. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anne-Laure Voisin, Bertrand Godeau, Christophe Massard, Vincent Ribrag, Aurélien Marabelle, Marc Michel, Olivier Lambotte - The Lancet Haematology 2018 cited by 292

  11. mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Immunity 2021 cited by 142

  12. Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Aurora Pujol, Marie Zins, Pierre Tiberghien, Paul Gray, Peter McNaughton, Anna Sullivan, Jane Peake, Romain Lévy, Laetitia Languille, Carlos Rodríguez‐Gallego, Bertrand Boisson, Sébastien Gallien, Bénédicte Neven, Marc Michel, Bertrand Godeau, Laurent Abel, F.A. Rey, Jean–Claude Weill, Claude–Agnès Reynaud, Stuart G. Tangye, Jean‐Laurent Casanova, Matthieu Mahévas - The Journal of Experimental Medicine 2022 cited by 47

  13. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2012 cited by 194

  14. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

    Authors: , , , , , , , , , , , , , , , , , , - Blood 2022 cited by 115

  15. Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia

    Authors: , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2021 cited by 87

  16. Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia

    Authors: , , , , , , , , , - Haematologica 2021 cited by 50

  17. DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2023 cited by 40

  18. Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life

    Authors: , , , , , , , , , , , , , , , , , - American Journal of Hematology 2020 cited by 119

  19. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients

    Authors: , , , , , , , , , , , , , , - Breast Cancer Research 2021 cited by 65

  20. Dopamine−Melanin Film Deposition Depends on the Used Oxidant and Buffer Solution

    Authors: , , , , , , , - Langmuir 2011 cited by 539

  21. High-affinity autoreactive plasma cells disseminate through multiple organs in patients with immune thrombocytopenic purpura

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2022 cited by 35

  22. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group

    Authors: , , , , , , , , , , , , , , , , , , , - Blood 2013 cited by 248

  23. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , L. Astudillo, C. Bélizna, Nadia Belmatoug, Olivier Benvéniste, A. Benyamine, Holly Bezanahary, Patrick Blanco, O Blétry, Bahram Bodaghi, Pierre Bourgeois, B. Brihaye, Emmanuel Chatelus, R. Damade, Éric Daugas, C. Degennes, Jean‐François Delfraissy, C. Delluc, Aurélien Delluc, P. Duhaut, Alain Dupuy, I. Durieu, E A Hang-Korng, Dominique Farge, Christian Funck‐Brentano, Frédérique Gandjbakhch, Justine Gellen‐Dautremer, Pascale Ghillani‐Dalbin, Bertrand Godeau, Cécile Goujard, C. Grandpeix, C. Grangé, Lamiae Grimaldi‐Bensouda, G. Guettrot-Imbert, Loïc Guillevin, É. Hachulla, Jean-Robert Harlé, Julien Haroche, Pierre Hausfater, Jean Jouquan, Gilles Kaplanski, Homa Keshtmand, Mehdi Khellaf, O. Lambotte, David Launay, H. Lévesque, Olivier Lidove, Eric Liozon, L Y Kim, Matthieu Mahévas, K. Mariampillai, Xavier Mariette, Alexis Mathian, K. Mazodier, Marc Michel, Nathalie Morel, Luc Mouthon, Rokiya Ngack, J. Ninet, Éric Oksenhendler, Jean‐Luc Pellegrin, Olivier Peyr, Anne‐Marie Piette, Vincent Poindron, Fabienne Roux, David Saadoun, Sabrinel Sahali, B. Saint-Marcoux, F. Sarrot-Reynauld, Y. Schoindre, Jérémie Sellam and 13 more - Annals of the Rheumatic Diseases 2012 cited by 206

  24. Long-Lived Plasma Cells in Autoimmunity: Lessons from B-Cell Depleting Therapy

    Authors: , , , - Frontiers in Immunology 2013 cited by 81